EP2683406A4 - ANTI-CD40 ANTIBODIES AND USES THEREOF - Google Patents

ANTI-CD40 ANTIBODIES AND USES THEREOF

Info

Publication number: EP2683406A4
Authority: EP; European Patent Office
Prior art keywords: antibodies
Prior art date: 2011-03-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP12758099.1A

Other languages

German (de)

French (fr)

Other versions

EP2683406B1 (en

EP2683406A2 (en

Inventor

Keith A Reimann

Rijian Wang

Christian P Larsen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Emory University

Beth Israel Deaconess Medical Center Inc

Original Assignee

Emory University

Beth Israel Deaconess Medical Center Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-03-11

Filing date

2012-03-12

Publication date

2014-09-24

2012-03-12 Application filed by Emory University, Beth Israel Deaconess Medical Center Inc filed Critical Emory University

2012-03-12 Priority to EP19156093.7A priority Critical patent/EP3556774B1/en

2012-03-12 Priority to DK19156093.7T priority patent/DK3556774T3/en

2012-03-12 Priority to EP23212999.9A priority patent/EP4338750A3/en

2012-03-12 Priority to PL12758099T priority patent/PL2683406T3/en

2012-03-12 Priority to SI201231620T priority patent/SI2683406T1/en

2014-01-15 Publication of EP2683406A2 publication Critical patent/EP2683406A2/en

2014-09-24 Publication of EP2683406A4 publication Critical patent/EP2683406A4/en

2019-05-08 Application granted granted Critical

2019-05-08 Publication of EP2683406B1 publication Critical patent/EP2683406B1/en

Status Active legal-status Critical Current

2032-03-12 Anticipated expiration legal-status Critical

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Mycology (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Zoology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

EP12758099.1A 2011-03-11 2012-03-12 Anti-cd40 antibodies and uses thereof Active EP2683406B1 (en)

Priority Applications (5)

Application Number	Priority Date	Filing Date	Title
EP19156093.7A EP3556774B1 (en)	2011-03-11	2012-03-12	Anti-cd40 antibodies and uses thereof
DK19156093.7T DK3556774T3 (en)	2011-03-11	2012-03-12	Anti-CD40 antibodies and uses thereof
EP23212999.9A EP4338750A3 (en)	2011-03-11	2012-03-12	Anti-cd40 antibodies and uses thereof
PL12758099T PL2683406T3 (en)	2011-03-11	2012-03-12	Anti-cd40 antibodies and uses thereof
SI201231620T SI2683406T1 (en)	2011-03-11	2012-03-12	ANTI-CD40 antibodies and their use

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161451870P	2011-03-11	2011-03-11
PCT/US2012/028782 WO2012125569A2 (en)	2011-03-11	2012-03-12	Anti-cd40 antibodies and uses thereof

Related Child Applications (3)

Application Number	Title	Priority Date	Filing Date
EP19156093.7A Division EP3556774B1 (en)	2011-03-11	2012-03-12	Anti-cd40 antibodies and uses thereof
EP19156093.7A Division-Into EP3556774B1 (en)	2011-03-11	2012-03-12	Anti-cd40 antibodies and uses thereof
EP23212999.9A Division EP4338750A3 (en)	2011-03-11	2012-03-12	Anti-cd40 antibodies and uses thereof

Publications (3)

Publication Number	Publication Date
EP2683406A2 EP2683406A2 (en)	2014-01-15
EP2683406A4 true EP2683406A4 (en)	2014-09-24
EP2683406B1 EP2683406B1 (en)	2019-05-08

Family

ID=46831289

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
EP19156093.7A Active EP3556774B1 (en)	2011-03-11	2012-03-12	Anti-cd40 antibodies and uses thereof
EP12758099.1A Active EP2683406B1 (en)	2011-03-11	2012-03-12	Anti-cd40 antibodies and uses thereof
EP23212999.9A Pending EP4338750A3 (en)	2011-03-11	2012-03-12	Anti-cd40 antibodies and uses thereof

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EP19156093.7A Active EP3556774B1 (en)	2011-03-11	2012-03-12	Anti-cd40 antibodies and uses thereof

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EP23212999.9A Pending EP4338750A3 (en)	2011-03-11	2012-03-12	Anti-cd40 antibodies and uses thereof

Country Status (15)

Country	Link
US (4)	US9987356B2 (en)
EP (3)	EP3556774B1 (en)
JP (1)	JP6170840B2 (en)
CN (2)	CN103596593B (en)
AU (3)	AU2012229236B2 (en)
CA (2)	CA3122934C (en)
DK (2)	DK3556774T3 (en)
ES (2)	ES2973062T3 (en)
FI (1)	FI3556774T3 (en)
HU (2)	HUE044591T2 (en)
PL (2)	PL2683406T3 (en)
PT (2)	PT2683406T (en)
SI (2)	SI2683406T1 (en)
TR (1)	TR201909840T4 (en)
WO (1)	WO2012125569A2 (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2032166T3 (en)	2006-06-13	2013-09-30	Oncomed Pharm Inc	Compositions and methods for diagnosing and treating cancer
AU2008209482B2 (en)	2007-01-24	2014-05-01	Oncomed Pharmaceuticals, Inc.	Compositions and methods for diagnosing and treating cancer
JP5560270B2 (en)	2008-07-08	2014-07-23	オンコメッドファーマシューティカルズインコーポレイテッド	NOTCH binding agents and antagonists and methods of use thereof
PT2349324T (en)	2008-10-17	2017-12-06	Sanofi Aventis Deutschland	Combination of an insulin and a glp-1 agonist
WO2011058083A1 (en)	2009-11-13	2011-05-19	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine
SG10201500871TA (en)	2009-11-13	2015-04-29	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist and methionine
AU2011202239C1 (en)	2010-05-19	2017-03-16	Sanofi	Long-acting formulations of insulins
RS55378B1 (en)	2010-08-30	2017-03-31	Sanofi Aventis Deutschland	USE OF AVE0010 FOR MANUFACTURE OF TREATMENT OF DIABETES MELLITUS TYPE 2
FI3556774T3 (en)	2011-03-11	2024-03-15	Beth Israel Deaconess Medical Ct Inc	ANTI-CD40 ANTIBODIES AND THEIR USES
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
HRP20151068T1 (en)	2011-08-29	2016-01-01	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
AR087744A1 (en)	2011-09-01	2014-04-16	Sanofi Aventis Deutschland	PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE
WO2014069655A1 (en) *	2012-11-05	2014-05-08	株式会社レグイミューン	Immune-tolerance inducer
AU2014247167B2 (en)	2013-04-03	2018-11-22	Sanofi	Treatment of diabetes mellitus by long–acting formulations of insulins
CN103467605B (en) *	2013-09-05	2015-02-04	武汉友芝友生物制药有限公司	CD3 antigen and preparation method and application thereof
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
WO2015154056A1 (en) *	2014-04-04	2015-10-08	Minnie Sarwal	Methods and compositions for the prediction and treatment of focal segmental glomerulosclerosis
US20170023576A1 (en) *	2014-04-04	2017-01-26	Oncomed Pharmaceuticals, Inc.	Notch3 antibodies and uses thereof
WO2016028810A1 (en) *	2014-08-18	2016-02-25	Biogen Ma Inc.	Anti-cd40 antibodies and uses thereof
CN105693845B (en) *	2014-11-24	2020-10-02	中国科学院上海营养与健康研究所	A kind of expression and purification of CD40 extracellular region and its use
JP6830437B2 (en)	2014-12-10	2021-02-17	リージェンツオブザユニバーシティオブミネソタ	Genetically modified cells, tissues and organs to treat the disease
TWI758239B (en)	2014-12-12	2022-03-21	德商賽諾菲阿凡提斯德意志有限公司	Insulin glargine/lixisenatide fixed ratio formulation
US9512229B2 (en)	2015-03-03	2016-12-06	Kymab Limited	Synergistic combinations of OX40L antibodies for the treatment of GVHD
TWI748945B (en)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	Treatment type 2 diabetes mellitus patients
TW201705975A (en)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	Treatment of type 2 diabetes mellitus patients
PE20180193A1 (en)	2015-05-29	2018-01-26	Abbvie Inc	ANTI-CD40 ANTIBODIES AND THEIR USES
KR101810778B1 (en)	2015-06-23	2017-12-20	서울대학교산학협력단	CD154 binding polypeptide and its use
HUE056769T2 (en) *	2015-09-04	2022-03-28	Primatope Therapeutics Inc	Humanized anti-cd40 antibodies and uses thereof
BR112018006360A2 (en)	2015-09-30	2018-10-09	Janssen Biotech Inc	agonistic antibodies that specifically bind to human cd40 and methods of use
JP6923528B2 (en) *	2015-12-15	2021-08-18	オーセイミュノセラピューティクスＯｓｅＩｍｍｕｎｏｔｈｅｒａｐｅｕｔｉｃｓ	Anti-CD28 humanized antibody prescribed for administration to humans
SG11201810509PA (en)	2016-06-20	2018-12-28	Kymab Ltd	Anti-pd-l1 antibodies
US11779604B2 (en)	2016-11-03	2023-10-10	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses and methods
EP4252629A3 (en)	2016-12-07	2023-12-27	Biora Therapeutics, Inc.	Gastrointestinal tract detection methods, devices and systems
US10766952B2 (en)	2017-03-02	2020-09-08	Beth Israel Deaconess Medical Center, Inc.	Methods for reducing migraine frequency in a subject in need thereof
EP3600416B1 (en)	2017-03-30	2023-06-07	Biora Therapeutics, Inc.	Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
KR102198998B1 (en) *	2017-06-01	2021-01-07	서울대학교 산학협력단	Novel anti-cd40 antibodies and uses thereof
CN112119092A (en)	2018-02-12	2020-12-22	无糖尿病公司	Improved antagonistic anti-human CD40 monoclonal antibodies
US20210251994A1 (en)	2018-06-15	2021-08-19	Flagship Pioneering Innovations V, Inc.	Increasing immune activity through modulation of postcellular signaling factors
WO2019246317A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease or condition in a tissue originating from the endoderm
US20230041197A1 (en)	2018-06-20	2023-02-09	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20220249814A1 (en)	2018-11-19	2022-08-11	Progenity, Inc.	Methods and devices for treating a disease with biotherapeutics
CN109481666B (en) *	2018-12-21	2020-11-03	江苏省中医院	Method for establishing PDX model of human blood tumor
MA55805A (en)	2019-05-03	2022-03-09	Flagship Pioneering Innovations V Inc	METHODS OF MODULATING IMMUNE ACTIVITY
BR112021022682A2 (en)	2019-05-14	2022-02-22	Provention Bio Inc	Methods and compositions for preventing type 1 diabetes
EP4309722A3 (en)	2019-12-13	2024-08-07	Biora Therapeutics, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP4076434A1 (en)	2019-12-17	2022-10-26	Flagship Pioneering Innovations V, Inc.	Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CA3182445A1 (en)	2020-06-11	2021-12-16	Francisco Leon	Methods and compositions for preventing type 1 diabetes
CN116096906A (en)	2020-06-29	2023-05-09	旗舰创业创新五公司	Virus engineered to promote saenox delivery and use thereof in treating cancer
JP2024512669A (en)	2021-03-31	2024-03-19	フラグシップパイオニアリングイノベーションズブイ，インコーポレーテッド	Tanotransmission polypeptides and their use in the treatment of cancer
JP2024523514A (en) *	2021-06-28	2024-06-28	江蘇恒瑞医薬股▲ふん▼有限公司	Anti-CD40 antibodies, antigen-binding fragments thereof, and medical uses
CA3224374A1 (en)	2021-06-29	2023-01-05	Flagship Pioneering Innovations V, Inc.	Immune cells engineered to promote thanotransmission and uses thereof
CN115768477A (en) *	2021-06-29	2023-03-07	舒泰神（北京）生物制药股份有限公司	Antibody specifically recognizing CD40 and application thereof
KR20240058075A (en) *	2021-07-14	2024-05-03	스테이드슨 (베이징) 바이오팔마슈티칼스 캄퍼니 리미티드	Antibodies specifically identifying CD40 and their applications
CN120463762A (en)	2021-08-26	2025-08-12	映恩生物科技(上海)有限公司	A steroid compound and its conjugate
US12234294B2 (en)	2021-11-05	2025-02-25	Kiniksa Pharmaceuticals, Gmbh	Pharmaceutical composition of a humanized anti-CD40 antibody
CN119110807A (en) *	2022-04-15	2024-12-10	百奥赛图(北京)医药科技股份有限公司	Anti-CD40 antibodies and uses thereof
WO2024077191A1 (en)	2022-10-05	2024-04-11	Flagship Pioneering Innovations V, Inc.	Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024151687A1 (en)	2023-01-09	2024-07-18	Flagship Pioneering Innovations V, Inc.	Genetic switches and their use in treating cancer
WO2025045766A1 (en)	2023-08-25	2025-03-06	Kiniksa Pharmaceuticals, Gmbh	Compositions comprising humanized anti-cd40 antibodies and methods for treating rheumatoid arthritis using the same
WO2025169146A1 (en)	2024-02-09	2025-08-14	Kiniksa Pharmaceuticals, Gmbh	Cd40 antagonist or cd154 antagonist for use in mitigating immune responses in protein and gene therapies
WO2025250691A1 (en) *	2024-05-28	2025-12-04	New York University	Anti-pik3ip1 antibodies and methods of use thereof

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3737433A (en)	1964-09-05	1973-06-05	Albert Ag Chem Werke	Certain oxoalkyldimethylxanthines
DE2819094A1 (en)	1977-05-10	1978-11-23	Sandoz Ag	CYCLOSPORIN DERIVATIVES, THEIR USE AND MANUFACTURING
FI65914C (en)	1978-03-07	1984-08-10	Sandoz Ag	FRAMEWORK FOR PHARMACEUTICAL COMPOSITION OF CYCLOSPORINE A
EP0056782B1 (en)	1981-01-09	1984-08-01	Sandoz Ag	Novel cyclosporins
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4576284A (en)	1983-12-02	1986-03-18	Warner-Lambert Company	Closing of filled capsules
US4894366A (en)	1984-12-03	1990-01-16	Fujisawa Pharmaceutical Company, Ltd.	Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
CH667274A5 (en)	1984-03-23	1988-09-30	Sandoz Ag	CYCLOSPORINE, THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
DE3438830A1 (en)	1984-10-23	1986-04-30	Rentschler Arzneimittel	PHARMACEUTICAL FORM CONTAINING NIFEDIPIN AND METHOD FOR THE PRODUCTION THEREOF
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8611905D0 (en)	1986-05-15	1986-06-25	Lilly Industries Ltd	Capsules
GB8729153D0 (en)	1987-12-14	1988-01-27	Efamol Ltd	Fatty acid compositions
ES2033086T3 (en)	1988-01-29	1993-03-01	Sankyo Company Limited	A PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION.
HU201567B (en)	1988-07-21	1990-11-28	Gyogyszerkutato Intezet	Process for production of intravenous medical compositions containing cyclosphorin
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
DE3919982A1 (en)	1989-06-19	1990-12-20	Liedtke Pharmed Gmbh	ORAL LIPID MEDICINE FORM
DE3920358A1 (en)	1989-06-22	1991-01-17	Behringwerke Ag	BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
JPH04230389A (en)	1990-07-16	1992-08-19	American Home Prod Corp	Rapamycin derivative
US5023262A (en)	1990-08-14	1991-06-11	American Home Products Corporation	Hydrogenated rapamycin derivatives
PT98990A (en)	1990-09-19	1992-08-31	American Home Prod	PROCESS FOR THE PREPARATION OF CARBOXYLIC ACID ESTERS OF RAPAMICIN
US5120842A (en)	1991-04-01	1992-06-09	American Home Products Corporation	Silyl ethers of rapamycin
US5100883A (en)	1991-04-08	1992-03-31	American Home Products Corporation	Fluorinated esters of rapamycin
US5118678A (en)	1991-04-17	1992-06-02	American Home Products Corporation	Carbamates of rapamycin
US5118677A (en)	1991-05-20	1992-06-02	American Home Products Corporation	Amide esters of rapamycin
US5120725A (en)	1991-05-29	1992-06-09	American Home Products Corporation	Bicyclic rapamycins
US5120727A (en)	1991-05-29	1992-06-09	American Home Products Corporation	Rapamycin dimers
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
GB9114948D0 (en)	1991-07-11	1991-08-28	Pfizer Ltd	Process for preparing sertraline intermediates
US5164495A (en)	1991-09-18	1992-11-17	Abbott Laboratories	Method for preparing a dicarboxylic acid half-acid ester of FK506
WO1993006213A1 (en)	1991-09-23	1993-04-01	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
US5151413A (en)	1991-11-06	1992-09-29	American Home Products Corporation	Rapamycin acetals as immunosuppressant and antifungal agents
GB9125660D0 (en)	1991-12-03	1992-01-29	Smithkline Beecham Plc	Novel compound
US5177203A (en)	1992-03-05	1993-01-05	American Home Products Corporation	Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5397703A (en) *	1992-07-09	1995-03-14	Cetus Oncology Corporation	Method for generation of antibodies to cell surface molecules
US5874082A (en)	1992-07-09	1999-02-23	Chiron Corporation	Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
ZA935112B (en)	1992-07-17	1994-02-08	Smithkline Beecham Corp	Rapamycin derivatives
US5234140A (en)	1992-07-28	1993-08-10	S. C. Johnson & Son, Inc.	Re-useable aerosol container
US5256790A (en)	1992-08-13	1993-10-26	American Home Products Corporation	27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en)	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
US5258389A (en)	1992-11-09	1993-11-02	Merck & Co., Inc.	O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
CA2172376C (en)	1993-10-01	2008-11-18	William C. Fanslow, Iii	Antibodies to cd40
EP0729471A1 (en)	1993-11-19	1996-09-04	Abbott Laboratories	Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US5827822A (en)	1996-03-25	1998-10-27	Sangstat Medical Corporation	Cyclosporin a formulations as nanoparticles
US5766629A (en)	1995-08-25	1998-06-16	Sangstat Medical Corporation	Oral cyclosporin formulations
US20030099642A1 (en)	1996-04-22	2003-05-29	Michael J. Yellin	Therapeutic applications for the anti-t-bam (cd40l) monoclonal antibody 5c8 in the treatment of vasculitis
WO1997022256A1 (en)	1995-12-19	1997-06-26	National Jewish Center For Immunology And Respiratory Medicine	Method to regulate cd40 signaling
WO1999029888A1 (en)	1997-12-05	1999-06-17	The Scripps Research Institute	Humanization of murine antibody
DE69916807T2 (en)	1998-02-04	2005-01-13	The General Hospital Corp., Boston	COSTIMULATORY BLOCKADE AND MIXED CHIMERISM IN ALLOTRANSPLANTATIONS
US6051228A (en)	1998-02-19	2000-04-18	Bristol-Myers Squibb Co.	Antibodies against human CD40
US6946129B1 (en)	1999-06-08	2005-09-20	Seattle Genetics, Inc.	Recombinant anti-CD40 antibody and uses thereof
EP1975182A1 (en)	2000-02-01	2008-10-01	PanGenetics B.V.	CD40-binding APC-activating molecules
WO2002011763A1 (en)	2000-04-19	2002-02-14	Tanox, Inc.	Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions
US7063845B2 (en)	2000-04-28	2006-06-20	Gemini Science, Inc.	Human anti-CD40 antibodies
PT1297017E (en)	2000-06-19	2012-09-04	Gen Hospital Corp	COMPOSITIONS AND METHODS OF MONOCLONAL AND POLYCLONAL ANTIBODIES SPECIFIC TO T-CELL SUBPOPULATIONS
CA2424296A1 (en)	2000-10-02	2002-04-11	Chiron Corporation	Human anti-cd40 antibodies
EP2009027B1 (en)	2001-04-27	2014-05-21	Kyowa Hakko Kirin Co., Ltd.	Anti-CD40 monoclonal antibody
AR039067A1 (en)	2001-11-09	2005-02-09	Pfizer Prod Inc	ANTIBODIES FOR CD40
AU2003217912A1 (en) *	2002-03-01	2003-09-16	Xencor	Antibody optimization
US20070098718A1 (en)	2003-11-04	2007-05-03	Chiron	Methods of therapy for b cell-related cancers
JP4765037B2 (en)	2003-11-04	2011-09-07	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	Use of antagonist anti-CD40 monoclonal antibodies for the treatment of chronic lymphocytic leukemia
PL1684805T3 (en)	2003-11-04	2010-12-31	Novartis Vaccines & Diagnostics Inc	Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
US8277810B2 (en)	2003-11-04	2012-10-02	Novartis Vaccines & Diagnostics, Inc.	Antagonist anti-CD40 antibodies
EP1694360B1 (en)	2003-11-04	2010-08-04	Novartis Vaccines and Diagnostics, Inc.	Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
PL1707627T3 (en)	2003-12-25	2013-04-30	Kyowa Hakko Kirin Co Ltd	Antagonistic anti-CD40 antibody mutant
SE0401601D0 (en)	2004-06-21	2004-06-21	Bioarctic Neuroscience Ab	Protofibril specific antibodies and uses thereof
EP1810979B1 (en)	2004-09-22	2012-06-20	Kyowa Hakko Kirin Co., Ltd.	STABILIZED HUMAN IgG4 ANTIBODIES
HRP20140271T1 (en)	2005-02-02	2014-05-23	University Of Massachusetts	Human antibodies against rabies and uses thereof
EP1885399B1 (en)	2005-05-26	2010-10-20	Seattle Genetics, Inc.	Humanized anti-cd40 antibodies and their methods of use
EP1904101A4 (en)	2005-06-08	2011-06-15	Univ Duke	ANTIBODY THERAPY AGAINST CD19 FOR TRANSPLANTATION PURPOSES
US8926979B2 (en)	2005-11-01	2015-01-06	Novartis Ag	Treatment of cancer or pre-malignant conditions using anti-CD40 antibodies
AU2006308860B2 (en)	2005-11-01	2012-01-12	Novartis Ag	Uses of anti-CD40 antibodies
WO2007075326A2 (en)	2005-12-09	2007-07-05	Seattle Genetics, Inc.	Methods of using cd40 binding agents
NZ571757A (en) *	2006-04-21	2012-01-12	Novartis Ag	Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
EP1854810A1 (en)	2006-05-09	2007-11-14	PanGenetics B.V.	Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
MX2009003323A (en)	2006-09-29	2009-08-28	Union Carbide Chem Plastic	Quaternized cellulose ethers for personal care products.
JP5721951B2 (en)	2007-03-22	2015-05-20	バイオジェンアイデックマサチューセッツインコーポレイテッド	Binding proteins that specifically bind to CD154, including antibodies, antibody derivatives, and antibody fragments, and uses thereof
CA2705263A1 (en)	2007-11-09	2009-05-14	Novartis Ag	Combination therapy with an antagonist anti-cd 40 antibody and cyclophosphamide, doxorubicin, vincristine and prednisone (chop) for treatment of b-cell malignancies
AU2009206506B2 (en) *	2008-01-23	2013-01-10	Xencor, Inc.	Optimized CD40 antibodies and methods of using the same
US8435514B2 (en)	2008-12-05	2013-05-07	Als Therapy Development Institute	Method for the treatment of neurodegenerative diseases
CA2754862C (en) *	2009-03-10	2019-04-02	Baylor Research Institute	Anti-cd40 antibodies and uses thereof
EP2552965A2 (en) *	2010-03-31	2013-02-06	Boehringer Ingelheim International GmbH	Anti-cd40 antibodies
AR083847A1 (en)	2010-11-15	2013-03-27	Novartis Ag	FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES
WO2012111762A1 (en)	2011-02-17	2012-08-23	協和発酵キリン株式会社	Highly concentrated anti-cd40 antibody pharmaceutical preparation
FI3556774T3 (en)	2011-03-11	2024-03-15	Beth Israel Deaconess Medical Ct Inc	ANTI-CD40 ANTIBODIES AND THEIR USES
ES2664619T3 (en)	2011-04-21	2018-04-20	Bristol-Myers Squibb Company	Antibody polypeptides that antagonize CD40
EP2951209A4 (en) *	2013-01-31	2016-06-22	Univ Jefferson	AGONISTSFUSION PROTEIN FOR CD40-OX40 AND USES THEREOF
GB201501613D0 (en)	2015-01-30	2015-03-18	Ucb Biopharma Sprl	Treatment of autoimmune disorders with CD154 antibodies
MA41459A (en)	2015-02-03	2017-12-12	Als Therapy Development Inst	ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L ILLNESSES OR DISORDERS
HK1252666A1 (en)	2015-06-29	2019-05-31	Bristol-Myers Squibb Company	Antibodies to cd40
HUE056769T2 (en)	2015-09-04	2022-03-28	Primatope Therapeutics Inc	Humanized anti-cd40 antibodies and uses thereof

2012
- 2012-03-12 FI FIEP19156093.7T patent/FI3556774T3/en active
- 2012-03-12 CN CN201280022277.3A patent/CN103596593B/en active Active
- 2012-03-12 DK DK19156093.7T patent/DK3556774T3/en active
- 2012-03-12 EP EP19156093.7A patent/EP3556774B1/en active Active
- 2012-03-12 EP EP12758099.1A patent/EP2683406B1/en active Active
- 2012-03-12 PL PL12758099T patent/PL2683406T3/en unknown
- 2012-03-12 SI SI201231620T patent/SI2683406T1/en unknown
- 2012-03-12 AU AU2012229236A patent/AU2012229236B2/en active Active
- 2012-03-12 WO PCT/US2012/028782 patent/WO2012125569A2/en not_active Ceased
- 2012-03-12 CA CA3122934A patent/CA3122934C/en active Active
- 2012-03-12 CN CN201610694457.6A patent/CN106279401A/en active Pending
- 2012-03-12 PL PL19156093.7T patent/PL3556774T3/en unknown
- 2012-03-12 DK DK12758099.1T patent/DK2683406T3/en active
- 2012-03-12 TR TR2019/09840T patent/TR201909840T4/en unknown
- 2012-03-12 SI SI201232057T patent/SI3556774T1/en unknown
- 2012-03-12 EP EP23212999.9A patent/EP4338750A3/en active Pending
- 2012-03-12 ES ES19156093T patent/ES2973062T3/en active Active
- 2012-03-12 JP JP2013557941A patent/JP6170840B2/en active Active
- 2012-03-12 PT PT12758099T patent/PT2683406T/en unknown
- 2012-03-12 HU HUE12758099 patent/HUE044591T2/en unknown
- 2012-03-12 US US14/004,552 patent/US9987356B2/en active Active
- 2012-03-12 HU HUE19156093A patent/HUE065915T2/en unknown
- 2012-03-12 CA CA2852056A patent/CA2852056C/en active Active
- 2012-03-12 ES ES12758099T patent/ES2733646T3/en active Active
- 2012-03-12 PT PT191560937T patent/PT3556774T/en unknown
2017
- 2017-08-18 AU AU2017216556A patent/AU2017216556B2/en active Active
2018
- 2018-05-29 US US15/991,432 patent/US10561728B2/en active Active
2019
- 2019-10-09 AU AU2019246821A patent/AU2019246821B2/en active Active
- 2019-12-13 US US16/714,191 patent/US20200261574A1/en not_active Abandoned
2022
- 2022-01-12 US US17/573,730 patent/US20220133887A1/en active Pending

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOON L ET AL: "Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys", TOXICOLOGY, LIMERICK, IR, vol. 174, 1 January 2002 (2002-01-01), pages 53 - 65, XP002954468, ISSN: 0300-483X, DOI: 10.1016/S0300-483X(02)00057-4 *
C. R. GILSON ET AL: "Anti-CD40 Monoclonal Antibody Synergizes with CTLA4-Ig in Promoting Long-Term Graft Survival in Murine Models of Transplantation", THE JOURNAL OF IMMUNOLOGY, vol. 183, no. 3, 10 July 2009 (2009-07-10), pages 1625 - 1635, XP055135164, ISSN: 0022-1767, DOI: 10.4049/jimmunol.0900339 *
HAANSTRA K G ET AL: "PREVENTION OF KIDNEY ALLOGRAFT REJECTION USING ANTI-CD40 AND ANTI-CD86 IN PRIMATES", TRANSPLANTATION, WILLIAMS AND WILKINS, BALTIMORE US, vol. 75, no. 5, 15 March 2003 (2003-03-15), pages 637 - 643, XP009040384, ISSN: 0041-1337, DOI: 10.1097/01.TP.0000054835.58014.C2 *
M. LUQMAN ET AL: "The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells", BLOOD, vol. 112, no. 3, 1 August 2008 (2008-08-01), pages 711 - 720, XP055024883, ISSN: 0006-4971, DOI: 10.1182/blood-2007-04-084756 *
See also references of WO2012125569A2 *

Also Published As

Publication number	Publication date
US20200261574A1 (en)	2020-08-20
EP3556774B1 (en)	2024-01-03
CN103596593A (en)	2014-02-19
CN103596593B (en)	2016-09-21
PL3556774T3 (en)	2024-07-01
FI3556774T3 (en)	2024-03-15
ES2973062T3 (en)	2024-06-18
CN106279401A (en)	2017-01-04
JP6170840B2 (en)	2017-07-26
AU2019246821A1 (en)	2019-10-31
EP2683406B1 (en)	2019-05-08
CA2852056A1 (en)	2012-09-20
AU2019246821B2 (en)	2021-01-14
AU2012229236A1 (en)	2013-10-24
JP2014509855A (en)	2014-04-24
CA2852056C (en)	2021-08-10
SI3556774T1 (en)	2024-06-28
US9987356B2 (en)	2018-06-05
TR201909840T4 (en)	2019-07-22
WO2012125569A2 (en)	2012-09-20
WO2012125569A3 (en)	2012-11-08
DK3556774T3 (en)	2024-03-25
US10561728B2 (en)	2020-02-18
AU2017216556B2 (en)	2019-08-15
DK2683406T3 (en)	2019-07-08
CA3122934C (en)	2025-09-02
SI2683406T1 (en)	2019-10-30
CA3122934A1 (en)	2012-09-20
US20140093497A1 (en)	2014-04-03
US20220133887A1 (en)	2022-05-05
HUE044591T2 (en)	2019-11-28
AU2017216556A1 (en)	2017-09-07
EP4338750A2 (en)	2024-03-20
EP3556774A1 (en)	2019-10-23
PT2683406T (en)	2019-07-08
PT3556774T (en)	2024-02-29
AU2012229236B2 (en)	2017-05-18
US20180344845A1 (en)	2018-12-06
ES2733646T3 (en)	2019-12-02
EP4338750A3 (en)	2024-05-15
PL2683406T3 (en)	2019-11-29
HUE065915T2 (en)	2024-06-28
EP2683406A2 (en)	2014-01-15

Publication	Publication Date	Title
FR21C1061I2 (en)	2022-11-18	ANTI-ANGPTL3 ANTIBODIES AND USES THEREOF
FR23C1023I2 (en)	2024-03-29	ANTI-IL-36R ANTIBODIES
FR24C1019I2 (en)	2025-03-28	ANTI-FCRN ANTIBODIES
EP2683406A4 (en)	2014-09-24	ANTI-CD40 ANTIBODIES AND USES THEREOF
EP2794654A4 (en)	2015-09-30	ANTI-PHF-TAU ANTIBODIES AND USES THEREOF
FR24C1027I2 (en)	2025-05-23	ANTIFUNGAL AGENTS AND THEIR USES
EP2718325A4 (en)	2015-03-11	ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
EP2668210A4 (en)	2015-09-02	ANTI-KIT ANTIBODIES AND USES THEREOF
EP2760889A4 (en)	2015-04-15	ANTIBODIES AGAINST TL1A AND USES THEREOF
EP2705039A4 (en)	2014-10-08	BROMODOMAIN INHIBITORS AND USES THEREOF
EP2726103A4 (en)	2015-06-03	ANTI-PROPERDINE ANTIBODIES AND USES THEREOF
EP2703486A4 (en)	2015-02-25	ANTIBODY ANTI-B7-H3
EP2930240A4 (en)	2016-07-13	ANTI-FOLR1 ANTIBODIES
EP2621955A4 (en)	2014-03-12	ANTI-CEACAM6 ANTIBODIES AND USES THEREOF
EP2825200A4 (en)	2015-08-26	HUMAN ANTI-CD27 ANTIBODIES, METHODS AND USES THEREOF
EP2970505A4 (en)	2016-10-19	BISPECIFIC ANTIBODIES AND USES THEREOF
EP2788377A4 (en)	2015-11-18	HER3 ANTIBODIES AND USES THEREOF
EP2922874A4 (en)	2016-10-19	BISPECIFIC ANTIBODIES
EP2530091A4 (en)	2013-07-10	ANTIBODY ANTI-DLL3
EP2981286A4 (en)	2016-08-24	ANTI-IL-4 ANTIBODIES AND BISPECIFIC ANTIBODIES AND USES THEREOF
EP2912065A4 (en)	2016-10-19	ANTIBODY ANTIBODY ANTIBODIES AND USES THEREOF
EP2885318A4 (en)	2016-03-30	PEPTIDE-DENDRIMER CONJUGATES AND USES THEREOF
EP2748192A4 (en)	2015-07-15	NOVEL KIF5B-RET FUSION MOLECULES AND USES THEREOF
EP2837685A4 (en)	2016-02-24	ANTI-FGFR2 ANTIBODIES
EP2771020A4 (en)	2015-11-11	N-ACYLDIPEPTIDE DERIVATIVES AND USES THEREOF

Legal Events

Date	Code	Title	Description
2013-12-13	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2014-01-15	17P	Request for examination filed	Effective date: 20131010
2014-01-15	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2014-06-18	DAX	Request for extension of the european patent (deleted)
2014-09-19	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1193347 Country of ref document: HK
2014-09-24	A4	Supplementary search report drawn up and despatched	Effective date: 20140826
2014-09-24	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 39/395 20060101AFI20140820BHEP Ipc: C07K 16/18 20060101ALI20140820BHEP
2016-12-23	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2017-01-25	17Q	First examination report despatched	Effective date: 20161222
2019-02-12	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Ref document number: 602012059898 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0039395000 Ipc: C07K0016280000
2019-03-12	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2019-03-12	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2019-03-20	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 16/28 20060101AFI20190212BHEP Ipc: A61K 39/395 20060101ALI20190212BHEP Ipc: A61P 37/06 20060101ALI20190212BHEP Ipc: A61K 38/13 20060101ALI20190212BHEP Ipc: A61K 45/06 20060101ALI20190212BHEP
2019-04-02	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2019-04-05	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2019-04-05	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2019-04-10	INTG	Intention to grant announced	Effective date: 20190313
2019-05-08	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2019-05-08	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2019-05-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 1130007 Country of ref document: AT Kind code of ref document: T Effective date: 20190515
2019-05-29	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602012059898 Country of ref document: DE Ref country code: IE Ref legal event code: FG4D
2019-06-25	REG	Reference to a national code	Ref country code: RO Ref legal event code: EPE
2019-07-08	REG	Reference to a national code	Ref country code: DK Ref legal event code: T3 Effective date: 20190704 Ref country code: PT Ref legal event code: SC4A Ref document number: 2683406 Country of ref document: PT Date of ref document: 20190708 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20190625
2019-07-10	REG	Reference to a national code	Ref country code: NL Ref legal event code: FP
2019-07-23	REG	Reference to a national code	Ref country code: SE Ref legal event code: TRGR
2019-08-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: NV Representative=s name: STOLMAR AND PARTNER INTELLECTUAL PROPERTY S.A., CH
2019-09-25	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG4D
2019-10-14	REG	Reference to a national code	Ref country code: NO Ref legal event code: T2 Effective date: 20190508
2019-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508
2019-11-05	REG	Reference to a national code	Ref country code: SK Ref legal event code: T3 Ref document number: E 31725 Country of ref document: SK
2019-11-28	REG	Reference to a national code	Ref country code: HU Ref legal event code: AG4A Ref document number: E044591 Country of ref document: HU
2019-11-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508
2019-12-02	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2733646 Country of ref document: ES Kind code of ref document: T3 Effective date: 20191202
2020-01-24	REG	Reference to a national code	Ref country code: GR Ref legal event code: EP Ref document number: 20190402380 Country of ref document: GR Effective date: 20191128
2020-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508
2020-02-11	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602012059898 Country of ref document: DE
2020-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508
2020-03-13	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2020-03-13	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2020-04-15	26N	No opposition filed	Effective date: 20200211
2020-10-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508
2020-12-28	REG	Reference to a national code	Ref country code: HU Ref legal event code: HC9C Owner name: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., US Ref country code: HU Ref legal event code: HC9C Owner name: EMORY UNIVERSITY, US
2022-02-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: UEP Ref document number: 1130007 Country of ref document: AT Kind code of ref document: T Effective date: 20190508
2022-06-01	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508
2022-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190908
2022-10-28	REG	Reference to a national code	Ref country code: HU Ref legal event code: HC9C Owner name: EMORY UNIVERSITY, US Ref country code: HU Ref legal event code: HC9C Owner name: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., US
2023-06-14	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230421
2025-04-08	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: SE Payment date: 20250312 Year of fee payment: 14
2025-04-11	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: PT Payment date: 20250318 Year of fee payment: 14 Ref country code: DE Payment date: 20250327 Year of fee payment: 14
2025-04-15	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DK Payment date: 20250325 Year of fee payment: 14 Ref country code: RO Payment date: 20250324 Year of fee payment: 14 Ref country code: FI Payment date: 20250325 Year of fee payment: 14 Ref country code: NL Payment date: 20250327 Year of fee payment: 14
2025-04-16	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: BG Payment date: 20250325 Year of fee payment: 14 Ref country code: LU Payment date: 20250327 Year of fee payment: 14
2025-04-17	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: HU Payment date: 20250326 Year of fee payment: 14
2025-04-22	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IE Payment date: 20250327 Year of fee payment: 14
2025-04-23	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: NO Payment date: 20250327 Year of fee payment: 14
2025-04-24	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: AT Payment date: 20250319 Year of fee payment: 14 Ref country code: GR Payment date: 20250331 Year of fee payment: 14 Ref country code: SI Payment date: 20250317 Year of fee payment: 14 Ref country code: BE Payment date: 20250327 Year of fee payment: 14
2025-04-25	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: PL Payment date: 20250331 Year of fee payment: 14 Ref country code: FR Payment date: 20250325 Year of fee payment: 14 Ref country code: CZ Payment date: 20250318 Year of fee payment: 14
2025-04-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: SK Payment date: 20250318 Year of fee payment: 14 Ref country code: IT Payment date: 20250319 Year of fee payment: 14 Ref country code: GB Payment date: 20250327 Year of fee payment: 14
2025-04-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: TR Payment date: 20250327 Year of fee payment: 14
2025-07-10	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: ES Payment date: 20250401 Year of fee payment: 14
2025-07-23	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CH Payment date: 20250401 Year of fee payment: 14